Disease diversity and FLT3 mutations

被引：5
|
作者：
Smith, Catherine Choy [1 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA
来源：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA | 2013年 / 110卷 / 52期
关键词：
ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; GASTROINTESTINAL STROMAL TUMORS; KINASE DOMAIN MUTATIONS; THERAPEUTIC TARGET; ITD MUTATIONS; RESISTANCE; VALIDATION; ACTIVATION; GEFITINIB;
D O I：
10.1073/pnas.1320579110
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：20860 / 20861
页数：2
相关论文
共 50 条
  • [1] Mechanisms of FLT3 inhibitor resistance by FLT3 double mutations
    Katayama, Kazuhiro
    CANCER SCIENCE, 2025, 116 : 1554 - 1554
  • [2] FLT3 mutations and leukaemia
    Kottaridis, PD
    Gale, RE
    Linch, DC
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (04) : 523 - 538
  • [3] FLT3 gene mutations in AML
    Mills, KI
    Gilkes, AF
    Walsh, V
    Sweeney, M
    Austin, SJ
    Gale, RE
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 29 - 29
  • [4] FLT3 mutations in myeloid sarcoma
    Ansari-Lari, MA
    Yang, CF
    Tinawi-Aljundi, R
    Cooper, L
    Long, P
    Allan, RH
    Borowitz, MI
    Berg, KD
    Murphy, KM
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (06) : 785 - 791
  • [5] Proteosomal degradation of Flt3 is stimulated by leukemia-associated Flt3 mutations.
    Robinson, LJ
    Xue, J
    BLOOD, 2004, 104 (11) : 705A - 705A
  • [6] Research on FLT3 mutations and targeted therapeutics
    Naoe, Tomoki
    Kiyoi, Hitoshi
    Yokota, Shohei
    CANCER SCIENCE, 2021, 112 : 1016 - 1016
  • [7] Prognostic relevance of FLT3 mutations in AML
    Blau, O.
    Berenstein, R.
    Sindarm, A.
    Baldus, C. D.
    Blau, I. W.
    ONKOLOGIE, 2011, 34 : 77 - 77
  • [8] Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia:: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors
    Kottaridis, PD
    Gale, RE
    Langabeer, SE
    Frew, ME
    Bowen, DT
    Linch, DC
    BLOOD, 2002, 100 (07) : 2393 - 2398
  • [9] Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition
    Brown, P
    Meshinchi, S
    Levis, M
    Alonzo, TA
    Gerbing, R
    Lange, B
    Arceci, R
    Small, D
    BLOOD, 2004, 104 (06) : 1841 - 1849
  • [10] Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy
    Ge, Shuai-Shuai
    Qiu, Qiao-Cheng
    Dai, Hai-Ping
    Shen, Xiang-Dong
    Wu, Tian-Mei
    Du, Jia-Hui
    Wan, Chao-Ling
    Shen, Hong-Jie
    Wu, De-Pei
    Xue, Sheng-Li
    Liu, Song-Bai
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, : 539 - 549
12345